PR Newswire Clinical TrialsOriginal article
New Progress -- XellSmart Unveiled Phase I Results of Off-the-Shelf Parkinson's Disease Cell Therapy at MDS & Completed Blinded Phase II Enrollment
Phase 1positiveXellSmart off-the-shelf cell therapyPositive
AI Analysis
Summary
XellSmart presented Phase I results for its off-the-shelf Parkinson's disease cell therapy at the MDS Congress and announced completion of blinded Phase II enrollment. The company is private; the known tickers (ISCO, WHEN) are not mentioned in the available text.
Clinical Trial Data
Phase
Phase 1/Phase 2
Outcome Details
Phase I results presented at MDS Congress; blinded Phase II enrollment completed. Article text is truncated, so detailed efficacy/safety data are not available.
Importance:4/10
Sentiment:
0.50
Parkinson's diseasecell therapyoff-the-shelfPhase I dataPhase II enrollmentMDS Congressneurology
Read the original article
Published by PR Newswire Clinical Trials on October 18, 2026 4:27 AM